We identified the druggable target, JAK2, as a strong selective gene dependency and a candidate therapeutic target in CBFA2T3::GLIS2 AML and identified resistance mechanisms and effective drug combinations with JAK2 inhibitors. This evidence concerns the gene JAK2 and acute myeloid leukemia.